Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
source: pixabay.com

Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases

  According to a recent article in Business Wire, it is estimated that five million people in the United States over the age of sixty-five are coping with Alzheimer’s at…

Continue Reading Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
source: pixabay.com

Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years

  Dr. Richard Furie at New York’s Feinstein Institutes recently interviewed with MedPage Today. Dr. Furie discussed the prognosis for lupus nephritis and belimumab (Benlysta), a recently-tested drug that appears…

Continue Reading Belimumab is the Second Drug to be Developed for Lupus in Over Fifty Years
Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements
source: pixabay.com

Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements

  This year, thanks to COVID-19, many conferences have been held online. These play a crucial role in spreading data, facilitating conversations, and determining potential treatment options for patients with…

Continue Reading Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements